| Summit Oral Surgery & Implant Center | |
|
625 Henry Chapple St. Billings MT 59106-1839 | |
| (406) 259-7438 | |
| (406) 259-9729 |
| Full Name | Summit Oral Surgery & Implant Center |
|---|---|
| Speciality | Dentist |
| Location | 625 Henry Chapple St., Billings, Montana |
| Authorized Official Name and Position | Roderick M Griffeth (OWNER) |
| Authorized Official Contact | 4062597438 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Summit Oral Surgery & Implant Center 625 Henry Chapple St Billings MT 59106-1839 Ph: (406) 259-7438 | Summit Oral Surgery & Implant Center 625 Henry Chapple St. Billings MT 59106-1839 Ph: (406) 259-7438 |
| NPI Number | 1073656567 |
|---|---|
| Provider Enumeration Date | 02/14/2007 |
| Last Update Date | 10/17/2022 |
| Medicare PECOS PAC ID | 2961460258 |
|---|---|
| Medicare Enrollment ID | O20050103001050 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073656567 | NPI | - | NPPES |
| 112397100 | Medicaid | WY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | (* (Not Available)) | Primary |
| Provider Name | Roderick M Griffeth |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1861727646 PECOS PAC ID: 7719165208 Enrollment ID: I20110705000471 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Mackay J Hull |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1184780421 PECOS PAC ID: 1658546924 Enrollment ID: I20111214001090 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Bert W Winterholler |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1841356094 PECOS PAC ID: 9830276823 Enrollment ID: I20111214001091 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Brian R Ludwig |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1083876478 PECOS PAC ID: 2567627755 Enrollment ID: I20120714000054 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Jesse L Gray |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1750678538 PECOS PAC ID: 1254563331 Enrollment ID: I20171024003704 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
| Provider Name | Logan A Ganoe |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1437504420 PECOS PAC ID: 6901183037 Enrollment ID: I20210824003421 |
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
News Archive
Cystic fibrosis patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug.
Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer's disease, but still little is known about the role the gene plays in the disease process.
MedVirginia has announced its participation in the Interoperability Showcase™ at the HIMSS11 Annual Conference & Exhibition in Orlando, Florida next week.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 1 days ago
Taylor Dental Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2700 Grand Ave Ste E, Billings, MT 59102 Phone: 406-652-9204 | |
Wicks Dental Clinic Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 502 Wicks Ln, Billings, MT 59105 Phone: 406-248-7868 Fax: 406-248-1768 | |
Turley Dental Care, Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 315 N 25th St, Suite 101, Billings, MT 59101 Phone: 406-248-6177 Fax: 406-248-1556 | |
Rubicon Dental Associates, Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 10 Avanta Way, Suite 3, Billings, MT 59102 Phone: 406-655-4210 Fax: 406-655-8100 | |
Wy Specialty Dental Services, Llc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 152 S 32nd St W, Billings, MT 59102 Phone: 406-245-4414 | |
Billings Oral Surgery & Dental Implant Center Dental Clinic Medicare: Medicare Enrolled Practice Location: 152 S 32nd St W Ste B, Billings, MT 59102 Phone: 406-245-4414 |